Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US-EU Mutual Reliance On Drug Facility Inspections Nears Reality

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA expects to complete work this year on decision model to determine whether an EU member state's inspectorate is capable of conducting inspections that meet US requirements.

You may also be interested in...

US Reliance On EU Drug Facility Inspections Begins In November

FDA will have completed capability assessments for eight European Union member country inspectorates by that time, with all 28 to be completed by mid-2019; EU assessment of US regulator’s inspection capabilities wraps up in July.

FDA Mutual Reliance With EU On Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

FDA Launches Global Rx Quality Initiative With Plans To Rely On Non-U.S. Regulators

Agency restructures staff as it prepares for new U.S.-EU mutual reliance activities to enhance pharmaceutical quality but offers few details on upcoming plans.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts